Semax side effects: what the trials report

Semax has no approved regulatory label in the EU, EEA, UK or US, which means no boxed warnings, no official adverse-event tables, and no post-marketing pharmacovigilance data from the FDA or the EMA^[1]. The safety picture that does exist comes from the Russian prescribing record and a body of clinical and preclinical publications, almost all in Russian-language journals. The honest framing is: the Russian experience is reassuring on acute use; the longer-horizon questions remain open.

What the Russian clinical record shows

Semax has been a prescription intranasal medicine in Russia since 7 December 2011^[2]. The longest published clinical experience summary is a 1997 paper by Ashmarin and colleagues covering 15 years of study and clinical application. The authors reported that at the registered intranasal doses of 0.015 to 0.050 mg/kg, Semax "in no case produced negative side actions or complications connected with its administration"^[3].

The most-cited Russian trial is a 2018 study by Gusev and colleagues in 110 patients at different stages of ischemic stroke, which evaluated the standard Russian regimen of two 10-day intranasal courses at 6,000 micrograms per day separated by a 20-day interval^[2]. The published abstract reports gains in BDNF plasma levels, improvements on the motor scale, and gains on the Barthel index of daily living activities. No adverse events are reported. The methodological caveat is that the PubMed abstract does not characterise the study as a fully randomised, placebo-controlled, double-blind trial, so the absence of reported adverse events reflects the study design as much as the safety profile.

The intranasal route means the most plausible local adverse effects are those common to any nasal spray: nasal irritation, transient stinging on application, and, at higher doses, potential rhinitis-like symptoms. None of the English-language abstracts of Russian clinical papers documents these in detail. The 2026 review by Mavrych and colleagues, which examined Semax in the context of neuroprotection and aging, noted that non-approved peptides in this class generally lack long-term safety data and systematic validation in Western evidentiary terms.

No boxed warnings, but also no Western safety dataset

A boxed warning only exists for approved medicines. Because the FDA, EMA, MHRA, and the national agencies in the EU and EEA have not authorised Semax, there is no approved label from which to read a structured adverse-event profile^[1]. The EMA has no marketing authorisation, EPAR, or referral for Semax. The FDA classifies it as unscheduled and not approved. That absence does not tell us Semax is dangerous; it tells us the safety data that would be required to support an approval has not been assembled or reviewed by those agencies.

The gap matters because Western regulatory review requires a safety dataset that a Russian national registration does not automatically generate for a foreign market: large-sample, multi-centre, randomised, placebo-controlled trials with pre-specified adverse-event collection, independent monitoring, and pharmacovigilance continuations. That dataset does not exist for Semax in our coverage area.

Mechanism-based considerations

Semax modulates BDNF levels, dopaminergic signalling, and serotoninergic signalling^[4][5]. The theoretical consideration from the dopaminergic modulation is that co-administration with stimulants could amplify effects in ways not yet studied in humans. The 2005 Eremin study in rodents found that Semax dramatically enhanced the locomotor and dopamine-release response to D-amphetamine, which is a rodent model finding rather than a clinical observation, but it suggests caution with co-administration of dopaminergic agents until human interaction data exists^[4].

A 2025 mouse spinal-cord-injury study found that Semax acts on the mu-opioid receptor gene Oprm1. The interaction with opioid-receptor biology has not been characterised in humans and is not part of the Russian prescribing information for the registered indications.

Grey-market supply as a separate risk

Outside Russia, Semax is sold through the same grey-market research-peptide channels that supply BPC-157 and ipamorelin. For readers in our coverage area, the regulatory picture is the starting point: no authorised supply exists. Independent testing of grey-market peptides as a category has documented frequent purity and identity failures, which means a person using grey-market Semax faces a compounding risk: the adverse-event question for the peptide itself, plus the additional question of what else might be in the vial. These are distinct risks that cannot be collapsed.

What we do not yet know

The Russian post-marketing record on acute intranasal use at the registered doses is the strongest safety signal available. Beyond that, the following questions have not been answered to Western-regulatory standards: the chronic-dosing safety profile at months-to-years of use; safety in pregnancy; safety in paediatric populations outside specific Russian neonatology protocols; safety in geriatric populations with the comorbidities common to that group; and the interaction profile with common prescription medicines. A 2026 review summarising Semax in the broader context of therapeutic peptides for aging explicitly flagged the absence of systematic long-term safety data as the limiting factor for wider adoption.

If you are considering Semax, these open questions are the ones to raise with a clinician who knows your medical history. The full Semax page covers the approved Russian indications, the mechanistic evidence, and the country-by-country regulatory status in detail.